Cargando…

Postpartum anticoagulation in women with mechanical heart valves

BACKGROUND: Women with mechanical heart valves (MHV) requiring anticoagulation (AC) are at high risk for hemorrhagic complications. Despite guidelines to manage antenatal and peripartum AC, there are few evidence-based recommendations to guide the initiation of postpartum AC. We reviewed our institu...

Descripción completa

Detalles Bibliográficos
Autores principales: Irani, Roxanna A, Santa-Ines, Ann, Elder, Robert W, Lipkind, Heather S, Paidas, Michael J, Campbell, Katherine H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207249/
https://www.ncbi.nlm.nih.gov/pubmed/30498374
http://dx.doi.org/10.2147/IJWH.S177547
_version_ 1783366489909231616
author Irani, Roxanna A
Santa-Ines, Ann
Elder, Robert W
Lipkind, Heather S
Paidas, Michael J
Campbell, Katherine H
author_facet Irani, Roxanna A
Santa-Ines, Ann
Elder, Robert W
Lipkind, Heather S
Paidas, Michael J
Campbell, Katherine H
author_sort Irani, Roxanna A
collection PubMed
description BACKGROUND: Women with mechanical heart valves (MHV) requiring anticoagulation (AC) are at high risk for hemorrhagic complications. Despite guidelines to manage antenatal and peripartum AC, there are few evidence-based recommendations to guide the initiation of postpartum AC. We reviewed our institutional experience of pregnant women with MHV to lay the groundwork for recommendations of immediate postpartum AC therapy. STUDY DESIGN: This descriptive retrospective cohort used ICD-9 and -10 codes to identify pregnant women with MHV on AC at the Yale-New Haven Hospital from 2007 to 2018. All identified patients were confirmed by chart review. Delivery hospitalization and the immediate postpartum AC management were reviewed. Maternal complications recorded were postpartum hemorrhage, transfusion, wound hematoma, intra-abdominal bleeding, stroke, valve thrombosis, and death. Further, immediate neonatal outcomes were detailed. RESULTS: Forty-two pregnant women with nonnative heart valves were identified during the study period. From those pregnant women, nine had an MHV and were anticoagulated throughout gestation. Of 19 total pregnancies, 14 met the inclusion criteria. The median gestational age of the delivered pregnancies was early term (37w2d). Nine deliveries were via cesarean (64%). The median time to restart AC after birth was 6 hours. After six deliveries (43%), AC was initiated ≤6 hours postpartum. Hemorrhagic complications occurred in six cases (43%), including wound and intra-abdominal hematomas. Four cases (29%) required blood transfusion. No maternal strokes, thrombotic events, or deaths were recorded. Five (38.5%) neonates required admission to the neonatal intensive care unit. CONCLUSION: MHV in pregnancy was rare but was associated with significant maternal morbidity, particularly postpartum hemorrhagic complications. We noted significant variability in the timing of restarting postpartum AC and in the selected agents. Pooled institutional data and an interdisciplinary approach are recommended to minimize competing risks and sequelae of valve thrombosis and obstetrical hemorrhage and, thereby, to optimize maternal outcomes and develop evidence-based guidelines for postpartum AC management.
format Online
Article
Text
id pubmed-6207249
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62072492018-11-29 Postpartum anticoagulation in women with mechanical heart valves Irani, Roxanna A Santa-Ines, Ann Elder, Robert W Lipkind, Heather S Paidas, Michael J Campbell, Katherine H Int J Womens Health Original Research BACKGROUND: Women with mechanical heart valves (MHV) requiring anticoagulation (AC) are at high risk for hemorrhagic complications. Despite guidelines to manage antenatal and peripartum AC, there are few evidence-based recommendations to guide the initiation of postpartum AC. We reviewed our institutional experience of pregnant women with MHV to lay the groundwork for recommendations of immediate postpartum AC therapy. STUDY DESIGN: This descriptive retrospective cohort used ICD-9 and -10 codes to identify pregnant women with MHV on AC at the Yale-New Haven Hospital from 2007 to 2018. All identified patients were confirmed by chart review. Delivery hospitalization and the immediate postpartum AC management were reviewed. Maternal complications recorded were postpartum hemorrhage, transfusion, wound hematoma, intra-abdominal bleeding, stroke, valve thrombosis, and death. Further, immediate neonatal outcomes were detailed. RESULTS: Forty-two pregnant women with nonnative heart valves were identified during the study period. From those pregnant women, nine had an MHV and were anticoagulated throughout gestation. Of 19 total pregnancies, 14 met the inclusion criteria. The median gestational age of the delivered pregnancies was early term (37w2d). Nine deliveries were via cesarean (64%). The median time to restart AC after birth was 6 hours. After six deliveries (43%), AC was initiated ≤6 hours postpartum. Hemorrhagic complications occurred in six cases (43%), including wound and intra-abdominal hematomas. Four cases (29%) required blood transfusion. No maternal strokes, thrombotic events, or deaths were recorded. Five (38.5%) neonates required admission to the neonatal intensive care unit. CONCLUSION: MHV in pregnancy was rare but was associated with significant maternal morbidity, particularly postpartum hemorrhagic complications. We noted significant variability in the timing of restarting postpartum AC and in the selected agents. Pooled institutional data and an interdisciplinary approach are recommended to minimize competing risks and sequelae of valve thrombosis and obstetrical hemorrhage and, thereby, to optimize maternal outcomes and develop evidence-based guidelines for postpartum AC management. Dove Medical Press 2018-10-25 /pmc/articles/PMC6207249/ /pubmed/30498374 http://dx.doi.org/10.2147/IJWH.S177547 Text en © 2018 Irani et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Irani, Roxanna A
Santa-Ines, Ann
Elder, Robert W
Lipkind, Heather S
Paidas, Michael J
Campbell, Katherine H
Postpartum anticoagulation in women with mechanical heart valves
title Postpartum anticoagulation in women with mechanical heart valves
title_full Postpartum anticoagulation in women with mechanical heart valves
title_fullStr Postpartum anticoagulation in women with mechanical heart valves
title_full_unstemmed Postpartum anticoagulation in women with mechanical heart valves
title_short Postpartum anticoagulation in women with mechanical heart valves
title_sort postpartum anticoagulation in women with mechanical heart valves
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207249/
https://www.ncbi.nlm.nih.gov/pubmed/30498374
http://dx.doi.org/10.2147/IJWH.S177547
work_keys_str_mv AT iraniroxannaa postpartumanticoagulationinwomenwithmechanicalheartvalves
AT santainesann postpartumanticoagulationinwomenwithmechanicalheartvalves
AT elderrobertw postpartumanticoagulationinwomenwithmechanicalheartvalves
AT lipkindheathers postpartumanticoagulationinwomenwithmechanicalheartvalves
AT paidasmichaelj postpartumanticoagulationinwomenwithmechanicalheartvalves
AT campbellkatherineh postpartumanticoagulationinwomenwithmechanicalheartvalves